{"id":46824,"date":"2026-04-10T16:16:32","date_gmt":"2026-04-10T16:16:32","guid":{"rendered":"https:\/\/foreignnewstoday.com\/?p=46824"},"modified":"2026-04-10T16:16:32","modified_gmt":"2026-04-10T16:16:32","slug":"novo-nordisks-glp-1-pill-momentum-faces-pricing-test-says-leading-bank","status":"publish","type":"post","link":"https:\/\/foreignnewstoday.com\/?p=46824","title":{"rendered":"Novo Nordisk&#8217;s GLP-1 pill momentum faces pricing test, says leading bank"},"content":{"rendered":"<p><br \/>\n<\/p>\n<div>\n<figure data-testid=\"article-figure-image\" class=\"yf-750ceo\">\n<div class=\"image-container yf-lglytj\" style=\"--max-height: 443px;\">\n<div class=\"image-wrapper yf-lglytj\" style=\"--aspect-ratio: 960 \/ 443; --img-max-width: 960px;\"><\/div>\n<\/div><figcaption class=\"yf-750ceo\"><!-- HTML_TAG_START -->Novo Nordisk&#8217;s GLP-1 pill momentum faces pricing test, says leading bank<span class=\"image-credit\"> Proactive uses images sourced from Shutterstock<\/span><!-- HTML_TAG_END -->  <\/figcaption><\/figure>\n<p class=\"yf-1fy9kyt\"><!-- HTML_TAG_START --><a href=\"https:\/\/finance.yahoo.com\/quote\/NVO\" data-ylk=\"slk:Novo Nordisk (NYSE:NVO);elm:context_link;itc:0;sec:content-canvas\" data-yga=\"{&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yLinkText&quot;:&quot;Novo Nordisk (NYSE&quot;}\" class=\"link \">Novo Nordisk (NYSE:NVO)<\/a> reports first-quarter 2026 results on 6 May, with UBS flagging that the results will provide the first meaningful look at the company&#8217;s economics at new, lower price points for its GLP-1 (glucagon-like peptide-1) obesity and diabetes drugs.<!-- HTML_TAG_END --><\/p>\n<p class=\"yf-1fy9kyt\"><!-- HTML_TAG_START -->The Danish pharmaceutical company has shed 27% of its market value year to date, hit by full-year 2026 guidance that came in significantly below market expectations and a disappointing clinical trial readout for CagriSema, a combination drug that proved inferior to rival Eli Lilly&#8217;s Zepbound in the REDEFINE-4 study.<!-- HTML_TAG_END --><\/p>\n<p class=\"yf-1fy9kyt\"><!-- HTML_TAG_START -->UBS highlights the oral version of Wegovy, the company&#8217;s flagship injectable weight-loss drug, as the key focus for investors, with weekly prescription volumes approaching 100,000 according to IQVIA data, though UBS notes those figures capture only around 60% of actual scripts written.<!-- HTML_TAG_END --><\/p>\n<p class=\"yf-1fy9kyt\"><!-- HTML_TAG_START -->The bank forecasts first-quarter oral Wegovy sales of $235 million, but cautions that a wide range of outcomes is possible given uncertainty around pricing across different sales channels, including direct patient support programmes, telehealth providers and commercial insurers.<!-- HTML_TAG_END --><\/p>\n<p class=\"yf-1fy9kyt\"><!-- HTML_TAG_START -->On the broader injectable Wegovy business, UBS notes that volume growth in the first quarter has been stronger than Novo&#8217;s own guidance assumed, raising the possibility that the company could lift the bottom end of its full-year sales growth guidance range, currently set at minus 5% to minus 13% on a constant exchange rate basis.<!-- HTML_TAG_END --><\/p>\n<p class=\"yf-1fy9kyt\"><!-- HTML_TAG_START -->Gross margin, which UBS estimates at 79% for the quarter, is flagged as a key unknown, with clarity expected to come when results land.<!-- HTML_TAG_END --><\/p>\n<p class=\"yf-1fy9kyt\"><!-- HTML_TAG_START -->UBS also points to the ongoing launch of Eli Lilly&#8217;s rival oral GLP-1 drug oforglipron as an additional risk to Novo&#8217;s momentum.<!-- HTML_TAG_END --><\/p>\n<p class=\"yf-1fy9kyt\"><!-- HTML_TAG_START -->UBS maintains its neutral rating on Novo Nordisk with a price target of DKr332.<!-- HTML_TAG_END --><\/p>\n<\/p><\/div>\n<p><br \/>\n<br \/><a href=\"https:\/\/finance.yahoo.com\/sectors\/healthcare\/articles\/novo-nordisks-glp-1-pill-160800236.html\">Source link <\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Novo Nordisk&#8217;s GLP-1 pill momentum faces pricing test, says leading bank Proactive uses images sourced from Shutterstock Novo Nordisk (NYSE:NVO) reports first-quarter 2026 results on 6&hellip;<\/p>\n","protected":false},"author":1,"featured_media":46825,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[31],"tags":[],"class_list":["post-46824","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-business-finance"],"_links":{"self":[{"href":"https:\/\/foreignnewstoday.com\/index.php?rest_route=\/wp\/v2\/posts\/46824","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/foreignnewstoday.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/foreignnewstoday.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/foreignnewstoday.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/foreignnewstoday.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=46824"}],"version-history":[{"count":0,"href":"https:\/\/foreignnewstoday.com\/index.php?rest_route=\/wp\/v2\/posts\/46824\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/foreignnewstoday.com\/index.php?rest_route=\/wp\/v2\/media\/46825"}],"wp:attachment":[{"href":"https:\/\/foreignnewstoday.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=46824"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/foreignnewstoday.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=46824"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/foreignnewstoday.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=46824"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}